WOS: 000388326300001PubMed: 27401586Background: Drug resistance development is an expected problem during treatment with protease inhibitors (PIs), this is largely due to the fact that Pls are low-genetic barrier drugs. Resistance-associated variants (RAVs) however may also occur naturally, and prior to treatment with Pls, the clinical impact of this basal resistance remains unknown. In Turkey, there is yet to be an investigation into the hepatitis C (HCV) drug associated resistance to oral antivirals. Materials and methods: 178 antiviral-naive patients infected with HCV genotype 1 were selected from 27 clinical centers of various geographical regions in Turkey and included in the current study. The basal NS3 Pls resistance mutations of the...
acknowledgments. Background and Aims: The first standard of care in treatment of chronic HCV genotyp...
Background: Hepatitis B virus (HBV) has a high mutation rate due to its unusual replication strategy...
AbstractDirect-acting antiviral (DAA)-based therapy is the new standard treatment for chronic hepati...
AbstractBackgroundDrug resistance development is an expected problem during treatment with protease ...
Background: Drug resistance development is an expected problem during treatment with protease inhibi...
The first standard of care in treatment of chronic HCV genotype 1 infection involving directly actin...
Background and objective: Presently, it has been approved to treat hepatitis C virus (HCV) infection...
Direct-acting antiviral agents (DAA) such as NS3 protease inhibitors is the first class of drugs use...
The first standard of care in treatment of chronic HCV genotype 1 infection involving directly actin...
Introduction: We report the prevalence and characteristics of DRMs associated with virological failu...
Boceprevir is a hepatitis C virus (HCV) nonstructural protein (NS) 3/4A protease inhibitor that is c...
Background: Protease inhibitors (PIs) to treat hepatitis C (HCV) virus infection have been approved ...
International audienceBackground: Hepatitis C virus (HCV) non-structural protein 5A (NS5A) inhibitor...
(See the editorial commentary by Fanning, on pages 797–9.) Background. The prevalence and clinical i...
Boceprevir is a hepatitis C virus (HCV) nonstructural protein (NS) 3/4A protease inhibitor that is ...
acknowledgments. Background and Aims: The first standard of care in treatment of chronic HCV genotyp...
Background: Hepatitis B virus (HBV) has a high mutation rate due to its unusual replication strategy...
AbstractDirect-acting antiviral (DAA)-based therapy is the new standard treatment for chronic hepati...
AbstractBackgroundDrug resistance development is an expected problem during treatment with protease ...
Background: Drug resistance development is an expected problem during treatment with protease inhibi...
The first standard of care in treatment of chronic HCV genotype 1 infection involving directly actin...
Background and objective: Presently, it has been approved to treat hepatitis C virus (HCV) infection...
Direct-acting antiviral agents (DAA) such as NS3 protease inhibitors is the first class of drugs use...
The first standard of care in treatment of chronic HCV genotype 1 infection involving directly actin...
Introduction: We report the prevalence and characteristics of DRMs associated with virological failu...
Boceprevir is a hepatitis C virus (HCV) nonstructural protein (NS) 3/4A protease inhibitor that is c...
Background: Protease inhibitors (PIs) to treat hepatitis C (HCV) virus infection have been approved ...
International audienceBackground: Hepatitis C virus (HCV) non-structural protein 5A (NS5A) inhibitor...
(See the editorial commentary by Fanning, on pages 797–9.) Background. The prevalence and clinical i...
Boceprevir is a hepatitis C virus (HCV) nonstructural protein (NS) 3/4A protease inhibitor that is ...
acknowledgments. Background and Aims: The first standard of care in treatment of chronic HCV genotyp...
Background: Hepatitis B virus (HBV) has a high mutation rate due to its unusual replication strategy...
AbstractDirect-acting antiviral (DAA)-based therapy is the new standard treatment for chronic hepati...